<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>96(43)</volume><submitter>Lu P</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Percutaneous nephrolithotomy (PCNL) and retrograde intrarenal surgery (RIRS) are widely used for pediatric upper tract stones; however, comparisons of their clinical efficacies are needed.&lt;h4>Methods&lt;/h4>Literature searches for relevant articles were performed using PubMed, the Cochrane Central Register of Controlled Trials, Embase and the China CNKI database. Study quality was assessed by Jadad and Newcastle-Ottawa Scales. Standard mean differences (SMDs) or odds ratios (OR), and 95% confidential intervals (95% CIs) were pooled for meta-analysis. In addition, data was evaluated the quality of the body of evidence by means of grading of recommendations assessment, development, and evaluation (GRADE).&lt;h4>Results&lt;/h4>Data from 4 studies (231 PCNL, 212 RIRS cases) were analyzed. There was no significant difference in operation time (SMD: 1.39; 95% CIs: -0.049 to 2.82; P = .058), overall stone-free rate (OR: 3.72; 95% CIs: 0.55-25.22; P = .18), or complication rate (OR: 1.92; 95% CIs: 0.90-4.07; P = .091). PCNL cases had longer hospital stays (SMD: 1.22; 95% CIs: 0.95-1.50; P &lt; .001), but showed a higher stone-free rate for stones greater than 20 mm (OR: 6.38; 95% CIs: 1.83-22.22; P = .004). For stones less than 20 mm, however, no significant difference between PCNL and RIRS was found (OR: 0.92; 95% CIs: 0.33-2.55; P = .87). The quality of evidence based on the GRADE system was low.&lt;h4>Conclusion&lt;/h4>Results of our systematic review and meta-analysis suggest that, for the treatment of larger kidney stones (>20 mm) in pediatric patients, PCNL is a better option due to its higher stone-free rate, although RIRS may be associated with shorter hospital stays. A large-scale clinical trial is necessary to validate our findings.</pubmed_abstract><journal>Medicine</journal><pagination>e8346</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5671844</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Clinical efficacy of percutaneous nephrolithotomy versus retrograde intrarenal surgery for pediatric kidney urolithiasis: A PRISMA-compliant article.</pubmed_title><pmcid>PMC5671844</pmcid><pubmed_authors>Zhang W</pubmed_authors><pubmed_authors>Yang J</pubmed_authors><pubmed_authors>Chen K</pubmed_authors><pubmed_authors>Qi K</pubmed_authors><pubmed_authors>Song R</pubmed_authors><pubmed_authors>Tao R</pubmed_authors><pubmed_authors>Gu M</pubmed_authors><pubmed_authors>Lu P</pubmed_authors><pubmed_authors>Yu Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clinical efficacy of percutaneous nephrolithotomy versus retrograde intrarenal surgery for pediatric kidney urolithiasis: A PRISMA-compliant article.</name><description>&lt;h4>Background&lt;/h4>Percutaneous nephrolithotomy (PCNL) and retrograde intrarenal surgery (RIRS) are widely used for pediatric upper tract stones; however, comparisons of their clinical efficacies are needed.&lt;h4>Methods&lt;/h4>Literature searches for relevant articles were performed using PubMed, the Cochrane Central Register of Controlled Trials, Embase and the China CNKI database. Study quality was assessed by Jadad and Newcastle-Ottawa Scales. Standard mean differences (SMDs) or odds ratios (OR), and 95% confidential intervals (95% CIs) were pooled for meta-analysis. In addition, data was evaluated the quality of the body of evidence by means of grading of recommendations assessment, development, and evaluation (GRADE).&lt;h4>Results&lt;/h4>Data from 4 studies (231 PCNL, 212 RIRS cases) were analyzed. There was no significant difference in operation time (SMD: 1.39; 95% CIs: -0.049 to 2.82; P = .058), overall stone-free rate (OR: 3.72; 95% CIs: 0.55-25.22; P = .18), or complication rate (OR: 1.92; 95% CIs: 0.90-4.07; P = .091). PCNL cases had longer hospital stays (SMD: 1.22; 95% CIs: 0.95-1.50; P &lt; .001), but showed a higher stone-free rate for stones greater than 20 mm (OR: 6.38; 95% CIs: 1.83-22.22; P = .004). For stones less than 20 mm, however, no significant difference between PCNL and RIRS was found (OR: 0.92; 95% CIs: 0.33-2.55; P = .87). The quality of evidence based on the GRADE system was low.&lt;h4>Conclusion&lt;/h4>Results of our systematic review and meta-analysis suggest that, for the treatment of larger kidney stones (>20 mm) in pediatric patients, PCNL is a better option due to its higher stone-free rate, although RIRS may be associated with shorter hospital stays. A large-scale clinical trial is necessary to validate our findings.</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Oct</publication><modification>2024-12-03T20:44:31.307Z</modification><creation>2019-03-27T03:00:56Z</creation></dates><accession>S-EPMC5671844</accession><cross_references><pubmed>29069011</pubmed><doi>10.1097/MD.0000000000008346</doi><doi>10.1097/md.0000000000008346</doi></cross_references></HashMap>